AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02744820 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching doses by oral route, once a day, 28 days
Study NCT02310126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A (multi-focal)
Description: Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
Study NCT01392430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of prophylactic drugs i.e. co-trimoxazole, dapsone, fluconazole, itraconazole, azithromycin
Description: Discontinuation of prophylaxis for opportunistic infections
Study NCT03694782 — intervention group
Intervention type: BEHAVIORAL
Intervention: Food diary supply
Description: Each participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops from the garden. Away-from-home food consumption was not recorded. For each food purchase, participants provided details of date, place of purchase, foods purchased (name, quantity and expense incurred), and trip made (origin/where the trip started, destination/where the trip ended, and mode of transportation). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary. To facilitate data entry, all family members were encouraged to help filling out the diary.
Study NCT03694782 — intervention group
Intervention type: BEHAVIORAL
Intervention: Actigraph
Description: Participants were instructed to wear a triaxial accelerometer (wGT3X-BT or wActiSleep-BT, Actigraph, Pensacola, FL, USA) fitted with an elastic strap on right side of the hip for 9 consecutive days, except for bathing and performing activities in the water. The Actigraph was accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
Study NCT03694782 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Participants received by email a link to complete an online questionnaire about mental and social health, sensibility to food waste, and connection with nature
Study NCT02646865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Enhanced Cognitive-Behavioral Therapy
Description: 12 group sessions of CBT for social anxiety based on Heimberg \& Becker's (2002) protocol with additional self-compassion exercises integrated into the treatment
Study NCT02646865 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Description: 12 group sessions of CBT for social anxiety based on Heimberg \& Becker's (2002) protocol
Study NCT04152174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined extracorporeal blood purification
Description: Patients receive combined extracorporeal blood purification: CRRT in CVVHDF mode with AN 69 ST set (Baxter) and hemoadsorption with Cytosorbents Corp. CytoSorb adsorber.
Study NCT04152174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRRT
Description: Patients receive CRRT in CVVHDF mode with AN 69 ST set (Baxter)
Study NCT03660020 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Local anesthetic
Description: ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy with local anaesthetics only
Study NCT03660020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronidase
Description: hyaluronidase will be added to ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy
Study NCT02310126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A (sphere)
Description: Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
Study NCT06403839 — intervention group
Intervention type: PROCEDURE
Intervention: No preoperative dental screening
Description: Discontinuance of mandatory preoperative dental screening prior surgical valve replacement which also can include oral surgery.
Study NCT01711242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study NCT01711242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT01711242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Study NCT02506959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT02506959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT02506959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02506959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02506959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT02506959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Given PO
Study NCT02506959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT01711242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT02506959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00832338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel with Cytoxan
Description: Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.
Study NCT00832338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
Study NCT00742105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGT226
Study NCT01414218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Humor as a Way of Life Seminar
Description: One session per week lasting 2-3 hours per session for 4 months. Sessions will include the videotaping of humorous stories or situations and instruction related to strategies to incorporate humor into everyday life.
Study NCT02693886 — intervention group
Intervention type: OTHER
Intervention: doctor experience
Study NCT02058498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log. Participants will be given the International Physical Activity Questionnaire and asked about their quality of life at baseline, at 6 weeks and at 4 months.
Study NCT01711242 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT03945279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB100
Description: Administered as specified in the treatment arm.
Study NCT03945279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT02154646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally
Study NCT02154646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study NCT02071940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: PLX3397 capsules 1000mg/day as monotherapy
Study NCT00743964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 50 mg/m2 iv on day 1
Study NCT03485989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hazelnuts
Description: Dry roasted, individually packaged hazelnuts provided from the Hazelnuts Marketing Board of Oregon
Study NCT01737814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT00743964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin, capecitabine
Description: Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
Study NCT00743964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, capecitabine
Description: Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
Study NCT01912898 — intervention group
Intervention type: DEVICE
Intervention: No intervention,The group with vitamin D deficient will be treated by the Endocrinology Department by loading of vitamin D
Study NCT01942863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water exchange single balloon enteroscopy
Description: Oral enteroscopy was performed first, followed by the anal route on the same day or later. For oral route, SBE was first advanced beyond Treitz ligation with CO2 insufflation. Then the water exchange method was used for further insertion. Briefly, residual air in the lumen was suctioned, and 37°C water was infused with a peristaltic pump through the biopsy channel to obtain lumen visualization. Turbid luminal water due to residual feces was suctioned and replaced by clean water until the small bowel lumen was clearly visualized again. Thus, infused water was removed predominantly during the insertion phase. The total volume of water was not restricted. For anal route, water exchange or CO2 insufflation method was used from the beginning of insertion respectively.
Study NCT01942863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 insufflation single balloon enteroscopy
Description: Conventional enteroscopy was performed as CO2 insufflated during insertion. Oral enteroscopy was performed first, followed by the anal route on the same day or later.
Study NCT01942863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Procedural Requirements
Description: SBE was advanced as deeply as possible and complete small bowel visualization was attempted. When the following conditions were met, tattooing at the deepest position with India ink was performed and the endoscope was withdrawn: no further endoscopic advancement could be achieved, detection of a significant lesion and no other lesions suspected, severe stricture, obvious sedation and SBE-related adverse events happened which required termination of further intubation.
Study NCT01737814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MST-188
Study NCT01942863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedural Requirements
Description: SBE was advanced as deeply as possible and complete small bowel visualization was attempted. When the following conditions were met, tattooing at the deepest position with India ink was performed and the endoscope was withdrawn: no further endoscopic advancement could be achieved, detection of a significant lesion and no other lesions suspected, severe stricture, obvious sedation and SBE-related adverse events happened which required termination of further intubation.
Study NCT02851992 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GTS cementless stem
Description: Total Hip Arthroplasty
Study NCT01283256 — intervention group
Intervention type: DRUG
Intervention: zonisamide
Description: zonisamide 100mg tablets
Study NCT01335971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane 25
Description: 25 micromoles (4.4 mg) sulforaphane daily by mouth
Study NCT01335971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane 150
Description: 150 micromoles (26.6 mg) sulforaphane daily by mouth
Study NCT01335971 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose once daily by mouth
Study NCT01948362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforadex
Description: Active compound
Study NCT01948362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha cyclodextrin
Description: Placebo control
Study NCT00772161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Comparison of two extended-release formulations of 20mg Methylphenidate in a cross-over design.
Study NCT02357420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin
Description: Double blind relamorelin was given subcutaneously BID for 12 weeks.
Study NCT02357420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given subcutaneously for 12 weeks.
Study NCT01991249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw
Study NCT02456337 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mucograft
Description: Coronally advanced flap associated to Xenogenous collagen matrix graft (mucograft) for the treatment of gingival recessions Miller Class I or II.
Study NCT02456337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucograft
Description: Coronally advanced flap associated to Xenogenous collagen matrix graft (mucograft) for the treatment of gingival recessions Miller Class I or II.
Study NCT02456337 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emdogain
Description: Coronally advanced flap associated to Enamel Matrix Derivative (Emdogain) for the treatment of gingival recessions Miller Class I or II.
Study NCT02456337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emdogain
Description: Coronally advanced flap associated to Enamel Matrix Derivative (Emdogain) for the treatment of gingival recessions Miller Class I or II.
Study NCT02456337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally Advanced flap
Description: Coronally advanced flap for the treatment of gingival recessions Miller Class I or II.
Study NCT02456337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Advanced flap
Description: Coronally advanced flap for the treatment of gingival recessions Miller Class I or II.
Study NCT02222896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: 2% CHG solution on cloth
Study NCT02222896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Excipients of CHG product only
Study NCT02222896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DynaHex-2
Description: 2% CHG solution
Study NCT00654329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline, given intranasally
Study NCT00654329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl, nasal transmucosal, 2 micrograms/kilogram
Study NCT01935895 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise on Blood Pressure Reactivity
Description: To comparison, volunteers randomly underwent 2 experimental sessions separated by 48-72h. The exercise session consisting of 3-laps in a circuit, performing resistance and aerobic exercises: knee extension, bench press, knee flexion, rowing in the prone, squat, shoulder press and five minutes of up to down in a 15cm high step between 75-85% heart rate maximum. Resistance exercise loads used dumbbells to upper body exercises and weights attached on the legs and arms to lower body exercises. Each resistance exercise was performed in 15reps with 50% of one repetition maximum test. Two secs for repetition were performed with rhythmic control. The control session was conducted under the same conditions of the exercise session, with the exception that subjects did not perform exercises.
Study NCT01324830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: day 1 to day 5
Description: low to high dose
Study NCT01324830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: day 1 to day 14
Description: low to high dose
Study NCT03445702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000mg once
Study NCT03445702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000mg once
Study NCT03445702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic metformin 1000mg
Study NCT02292849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer to Peer
Description: 12 weekly sessions of peer-delivered behavioral activation
Study NCT02292849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mental Health Referral
Description: Standard mental health referral to a community agency
Study NCT03760588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sacubitril/valsartan
Description: Target dose 97/103 mg b.i.d .
Study NCT03760588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Description: Target dose 97/103 mg b.i.d .
Study NCT01941589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
Description: maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
Study NCT01941589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids only
Description: IV corticosteroids only
Study NCT00654329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine, transmucosal, 1 microgram/kilogram
Study NCT00654329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine, 2 microgram/kilogram, transmucosal route
Study NCT03103932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker guided discharge algorithm
Description: participants randomized to the biomarker guided discharge algorithm will follow a pre-determined care pathway for treatment of heart failure symptoms based on admission NTproBNP levels
Study NCT02264496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT00974636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Salt Diet
Description: Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day
Study NCT00974636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Usual Salt Diet
Description: Usual salt intake (approximately >180-200 mmol/day in the average American diet).
Study NCT03237962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: High Flow Nasal Cannula (HFNC) is an oxygen device that increases oxygenation and washes out CO2 within the dead space, it was also clinically used to correct hypoxemia, hypercapnia and respiratory failure.By providing flow rate that is similar to or higher than the patient's inspiratory flow, HFNC is able to provide ventilatory support. To produce stable oxygen concentration, HFNC entrains less air in order to reach the preset value.
Study NCT03237962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Cannula
Description: Nasal cannula is an oxygen therapy device that has been commonly used as treatment for patients with hypoxemia. With the adjustable flow of 1-6Lpm, the concentration of the oxygen differs as the breathing pattern of the patient changes.
Study NCT05298462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Livzon Rapid Antibody Test for COVID-19
Description: Point-of-care Rapid Antibody Test for COVID-19
Study NCT02111213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Advisor
Description: The virtual advisor is named Carmen. She is an animated, computer-generated figure that speaks to participants and gives advice and support for physical activity.
Study NCT02111213 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Promotora for physical activity
Description: A promotora is a trained, lay health worker. Promotoras will be trained and supervised to provide advice, support and guidance to people to encourage them to be more physically active. They work with people face to face and by telephone to offer support and advice.
Study NCT02300389 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT boost radiotherapy
Description: All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
Study NCT02300389 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fractionated IMRT boost radiotherapy
Description: All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
Study NCT03906981 — intervention group
Intervention type: OTHER
Intervention: Plaque from each subject will be collected but there will be no intervention
Description: No intervention